What question did this study set out to answer?

This study aims to evaluate the outcomes of melanoma brain metastases treated with SRS and concurrent ipi/nivo, particularly the effect of prior therapies.

February 19, 2026The OncologistOpen Access

Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted Therapy

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the outcomes of melanoma brain metastases treated with SRS and concurrent ipi/nivo, particularly the effect of prior therapies.
Retrospective analysis of 68 patients with 413 melanoma brain metastases.
Evaluation of overall survival and intracranial progression-free survival as primary endpoints.
Assessment of factors influencing outcomes using univariable and multivariable Cox models.
Median overall survival was 24.0 months, with 12- and 24-month survival rates of 64% and 50%, respectively.
Patients naive to immune checkpoint inhibitors had longer overall survival compared to those treated prior (50.5 vs 17.6 months).
Presence of prior ICI and targeted therapy predicted poorer outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Reports combined SRS and ipilimumab/nivolumab outcomes in melanoma brain metastases, suggesting prior therapy influences survival.

Cite This Study

Messing et al. (2026) studied this question.

synapsesocial.com/papers/6996a80aecb39a600b3ee652 https://doi.org/10.1093/oncolo/oyag043

View Full Paper

Ask AI

Bookmark

Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted Therapy

Key Points

Discussion

Implication

Cite This Study

Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted Therapy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider